Dr. Yasmin Thanavala on targeted therapy for liver cancer
2 Pogledi
• 06/28/23
0
0
Ugraditi
administrator
Pretplatnici
Yasmin Thanavala, PhD, of the Department of Immunology and the Tumor Immunology and Immunotherapy program at Roswell Park Cancer Institute, discusses new research that may help identify those patients with advanced liver cancer who will benefit most from the targeted therapy sorafenib. Read more: http://goo.gl/W0jPX2
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari